In 2023, the GDP of New Hampshire amounted to around 93.47 billion U.S. dollars. The finance, insurance, real estate, rental, and leasing industry added the most real value to the gross domestic product of the state, amounting to 20.36 billion U.S. dollars. Comparatively, the mining, quarrying, and oil and gas extraction industry added around 155 million U.S. dollars worth of value to the state's GDP.

The Ibuprofen Active Pharmaceutical Ingredient (API) industry is predicted to experience steady growth over the forecast period, expanding at a CAGR of 4.80%. Its market size is estimated at XX million in 2025, with a projected value of XX million by 2033. The increasing prevalence of chronic pain and common ailments, such as headaches and arthritis, drives the demand for Ibuprofen. Moreover, the growing acceptance of over-the-counter (OTC) medications and the expansion of the pharmaceutical sector contribute to market growth. Significant trends shaping the Ibuprofen API industry include the rise of biosimilars, increasing preference for affordable generic medications, and growing awareness about pain management. However, factors such as stringent regulatory requirements and intense competition may restrain market growth. Key players in the industry include Solara Active Pharma Sciences, SI Group, BASF, Granules India, Athenex, and Strides Pharma Science. Regional markets like North America, Europe, Asia Pacific, Middle East and Africa, and South America exhibit varying growth patterns due to differences in healthcare infrastructure, regulatory policies, and disease prevalence. Recent developments include: November 2022: Solara Active Pharma Sciences Limited's new cutting-edge, multipurpose API manufacturing facility in Vishakhapatnam, Andhra Pradesh, received Certificate of Suitability (CEP) approval for manufacturing ibuprofen API from the European Directorate for the Quality of Medicine (EDQM)., March 2022: Lonza invested USD 935 million to build sites in Portsmouth, New Hampshire, and Visp, Switzerland. The company completed a laboratory expansion project at its API manufacturing facility in Nansha, China, in August 2021.. Key drivers for this market are: Upsurge in Pharmaceutical and Biopharmaceutical Production, Growing Prevalence of Chronic Disorders. Potential restraints include: Rising Production Costs. Notable trends are: Arthritis Holds a Significant Share in the Ibuprofen API Market.